RxDoctor Payments Data

Deepak Sobti, MD

Ophthalmology · Waxahachie, TXNPI 1790002814

Payments from drug & device makers

$55,599in general payments, 2019–2025

Across 165 payments — averaging $336.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$50K
  • Biotissue Holdings Inc.$2K
  • Johnson & Johnson Surgical Vision, Inc.$889
  • Alcon$740
  • AbbVie$473
  • Amgen$179
  • plus $677 from 12 others

What the payments were for

  • Consulting fees$18,64573%
  • Speaking & faculty fees$260%
  • Travel & lodging$7983%
  • Food & beverage$5,85023%
  • Education$1291%
  • Gifts$450%
  • Entertainment$1060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,599 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$359,840
Medicare patients
510
Services billed
1,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost51$25,140
XiidraLifitegrast29$20,993
RestasisCyclosporine31$20,094
Restasis MultidoseCyclosporine20$14,374
SimbrinzaBrinzolamide/Brimonidine Tart46$10,889
Travoprost46$8,827
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol48$7,490
Latanoprost688$7,060
Prednisolone Acetate221$6,619
CombiganBrimonidine Tartrate/Timolol21$6,061
Lotemax SmLoteprednol Etabonate24$5,994
Loteprednol Etabonate30$3,995
LotemaxLoteprednol Etabonate11$3,816
Timolol Maleate220$3,381
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat133$2,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Restasis Multidose, Combigan$473$65,669123 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate, Lotemax$38$13,80565 claims
AlconSimbrinza$740$10,88946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Waxahachie

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →